Table 1.
Assay specific sensitivities and terms used to report HCV RNA results.
Table 2.
Baseline patient characteristics.
Table 3.
Overall concordance of HCV RNA measurements between the CAP/CTM Ver. 1, the CAP/CTM Ver. 2 and the ART (n = 247).
Fig 1.
Quantitative HCV RNA at specific RGT timepoints during antiviral therapy.
Comparison of HCV RNA results of the Roche COBAS AmpliPrep/COBAS TaqMan HCV quantitative assay Version 1 (CAP/CTM Ver. 1), the Roche COBAS AmpliPrep/COBAS TaqMan HCV quantitative assay Version 2 (CAP/CTM Ver. 2) and the Abbott RealTime HCV (ART) assay in serum samples taken at (A) week 4/8 (n = 102), (B) week 12 (n = 73) and (C) week 24 (n = 72) during antiviral therapy. TND: Target not detected. <LLOQ: Below the lower limit of quantification
Fig 2.
Shortening of antiviral therapy (triple therapy regimen) according to assay specific detection of HCV RNA (n = 13).
According to the routine assay for guidance of treatment response (Roche COBAS AmpliPrep/COBAS TaqMan HCV quantitative assay Version 1 (CAP/CTM Ver. 1) 13 patients underwent an abbreviated course of antiviral therapy (24 weeks). In comparison: number and therapy outcome of patients who would have been eligible for a shortening of antiviral treatment according to the results of the Roche COBAS AmpliPrep/COBAS TaqMan HCV quantitative assay Version 2 (CAP/CTM Ver. 2), according to the Abbott RealTime HCV assay (ART) and the adapted version of the ART Abbott RealTime HCV assay (column ART adapted: shortening of antiviral treatment also in cases where HCV RNA was detected but <LLOQ at week 4/8 by ART).